Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis

NCT01687179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Lymphangioleiomyomatosis

Interventions

DRUG: "Sirolimus" and "Hydroxychloroquine" 200 mg
DRUG: "Sirolimus" and "Hydroxychloroquine" 400 mg

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]